Barclays Maintains Overweight on Bruker, Raises Price Target to $53

Benzinga Newsdesk www.benzinga.com Positive 83.5%

Neg 0% Neu 0% Pos 83.5%

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the price target from $45 to $53.